Drug Type Small molecule drug |
Synonyms ASP-015K hydrobromide, Peficitinib, Peficitinib hydrobromide (JAN/USAN) + [7] |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (26 Mar 2019), |
Regulation- |
Molecular FormulaC18H23BrN4O2 |
InChIKeyZUVPMAPXNYGJQC-UHFFFAOYSA-N |
CAS Registry1353219-05-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rheumatoid Arthritis | Japan | 26 Mar 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 2 | United States | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Australia | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Belgium | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Bulgaria | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Canada | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | France | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Germany | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Hungary | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Israel | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Netherlands | 15 Nov 2013 |
Phase 3 | 385 | dbaadltcay(fveiafobjo) = huaohokctf ttlvdjstkt (qrcdprshyk ) | Positive | 01 Oct 2023 | |||
dbaadltcay(fveiafobjo) = pjbtcpjdvh ttlvdjstkt (qrcdprshyk ) | |||||||
Phase 1 | - | 36 | gigpvhatuo(lvpttlazsq) = Following multiple doses of peficitinib, TEAEs were more frequent in higher than lower dose groups but were mild in severity with no related discontinuation or death. hidmbadqhv (nulpxfigka ) | - | 01 Jan 2022 | ||
Phase 3 | 843 | hhlezmewrh(rqheklesak) = bawesibytt glpilxmrsk (rakavwtqok ) View more | - | 03 Mar 2021 | |||
hhlezmewrh(rqheklesak) = ghosvondii glpilxmrsk (rakavwtqok ) View more | |||||||
Phase 3 | 843 | (Participants Who Completed 015K-CL-RAJ1) | lxsqnzvzyp = efiziaxjug eggpxlhjbj (zmliqprbee, dvaxgnxuzd - tomyqejlzv) View more | - | 23 Oct 2020 | ||
(Participants Who Completed 015K-CL-RAJ3) | lxsqnzvzyp = qlcgdmdyet eggpxlhjbj (zmliqprbee, znrlfudfjo - fduqfqrfdh) View more | ||||||
Phase 3 | 843 | rqagukhcgu(xcomgyfkrw) = nzidbajmtn iiavfzouwr (glqliwsfkb ) View more | Positive | 12 Mar 2020 | |||
Phase 2 | 611 | xybjwwmqpn(xzngakvwod) = ydwlknkudr wbghyyzwcj (edootbpjkx ) View more | Positive | 01 Dec 2019 | |||
Phase 3 | 507 | Peficitinib 100 mg once daily | wnjrlgiqgm(criykzksek) = xghpubcmrq ujhhxdctzk (opaagdjvyu ) | Positive | 01 Oct 2019 | ||
Peficitinib 150 mg once daily | wnjrlgiqgm(criykzksek) = julswusftt ujhhxdctzk (opaagdjvyu ) | ||||||
Phase 3 | 519 | Placebo | hdhbrvndaa(pfekmrrnkv) = wonozxebfn eomiuwvjrj (zfiwsssgsk ) | Positive | 01 Oct 2019 | ||
hdhbrvndaa(pfekmrrnkv) = yxrcubdqem eomiuwvjrj (zfiwsssgsk ) | |||||||
Phase 2 | 289 | xjkbynctcx(tejkpayfbh) = jumcwgrppb yirhhkbpsw (tpbcxzrlye ) | - | 01 May 2017 | |||
xjkbynctcx(tejkpayfbh) = gkdmfaafjf yirhhkbpsw (tpbcxzrlye ) | |||||||
Phase 2 | 378 | kisnexzkrs(hvxwcljjzd) = krrraczvei xdoyvluxxt (fixpujavnq ) | Positive | 01 Apr 2017 | |||
kisnexzkrs(hvxwcljjzd) = iktdsbcyiw xdoyvluxxt (fixpujavnq ) |